Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Cefepime/zidebactam Administered as Multiple IV Doses in Healthy Human Volunteers

Next Previous
Trial Profile

A Double-Blind Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Cefepime/zidebactam Administered as Multiple IV Doses in Healthy Human Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 12 May 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zidebactam (Primary) ; Cefepime
  • Indications Gram-negative infections
  • Focus Adverse reactions; Pharmacokinetics

    • Most Recent Events

    • 12 May 2017 Results assessing safety, tolerability and pharmacokinetics of Zidebactam and WCK 5222 using patient data from two double blind MAD studies (See CTPs 284673 and 284682), presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases
    • 12 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top